EAACI Congress 2024 Valencia, Spain 31 May - 3 June

Revolutionising Patient Care Through the Power of Data Science



#EAACIcongress

www.eaaci.org

inni pos

VALENCIA

Identifying KIT D816V Mutation in Patients With Evidence of Systemic Mast Cell Activation (MCA) and Enriched for Hereditary Alphatryptasemia (HaT): Results From the PROSPECTOR Clinical Trial

K. Hartmann,¹ I. Alvarez-Twose,² B. Myers,³ A. Hirdt,^{4,5} C. B. Livideanu,⁶ J. A. Bernstein,⁷ P. Lugar,⁸ A. F. Whyte,⁹ J. Anderson,¹⁰ F. Ruëff,¹¹ F. Siebenhaar,^{12,13} A. Zakharyan,¹⁴ G. Hoehn,¹⁴ C. Akin,¹⁵ V. Sabato¹⁶

¹University Hospital Basel and University of Basel, Basel, Switzerland; ²Institute of Mastocytosis Studies of Castilla-La Mancha, Toledo, Spain; ³University Hospitals of Leicester, Leicester, United Kingdom; ⁴Private Practice, New Paltz, NY, United States of America; ⁵Clinical Mentor, NYITCOM, Old Westbury, NY, United States of America; ⁶CEREMAST CHU de Toulouse, Toulouse, France; ⁷University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, OH, United States of America; ⁸Duke University Medical Center, Durham, NC, United States of America; ⁹University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom; ¹⁰ClinicalResearch Center of Alabama, Birmingham, AL, United States of America; ¹¹University Hospital, LMU Munich, Munich, Germany; ¹²Institute of Allergology, Charité –Universitätsmedizin, Berlin, Germany; ¹³Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; ¹⁴Blueprint Medicines Corporation, Cambridge, MA, United States of America; ¹⁵University of Michigan, Ann Arbor, MI, United States of America; ¹⁶University of Antwerp and Antwerp University Hospital, Antwerp, Belgium

......



Abstract 000403 31 May – 3 June, 2024

Disclosures

Dr Hartmann is a consultant for and has received travel support from ALK-Abelló, Allergopharma, BioCryst, Blueprint Medicines Corporation, Cogent, Galderma, KalVista, Leo, Menarini, Novartis, Pfizer, Sanofi, Takeda, and Thermo Fisher, and has received research funding from Thermo Fisher Scientific. Dr Alvarez-Twose is a consultant/speaker for and has received honoraria from Blueprint Medicines Corporation and Novartis. Dr Myers has no conflict of interests to disclose. Dr Hirdt has no conflict of interests to disclose. Dr Livideanu has no conflict of interests to disclose. Dr Bernstein is a consultant for Blueprint Medicines Corporation, Cogent, and Telios. Dr Lugar is a speaker/advisor for Blueprint Medicines Corporation and Grifols and is involved in research/clinical trials with Blueprint Medicines Corporation and BioMarin. Dr Whyte has no conflict of interests to disclose. Dr Anderson is a speaker for Blueprint Medicines Corporation and is involved in clinical research for Novartis, Celldex, Blueprint Medicines Corporation, and Genentech. Dr Ruëff has received personal fees for lectures from ALK-Abelló Arzneimittel GmbH, Allergopharma GmBH & Co. KG, Blueprint Medicines Corporation, Boehringer Ingelheim, Mylan Germany Team, Novartis, Thermo Fisher Diagnostics Austria GmbH, and UCB Pharma GmBH. Dr Siebenhaar is a speaker/advisor for and has received research funding from Allakos, Blueprint Medicines Corporation, Celldex, Cogent, Escient, Granular, GSK, InveaTx, Moxie, Noucor, Novartis, Sanofi/Regeneron, and ThirdHarmonicBio. Dr Zakharyan is a current employee of Blueprint Medicines Corporation. Dr Hoehn is a former employee of Blueprint Medicines Corporation. Dr Akin is a consultant for Blueprint Medicines Corporation, Cogent, and Novartis and has received research funding from Blueprint Medicines Corporation and Cogent. Dr Sabato is a speaker/advisor for Blueprint Medicines Corporation and Cogent and has received honoraria from Blueprint Medicines Corporation, Cogent, and Novartis and research funding from Blueprint Medicines Corporation.


www.eaaci.org

#EAACIconaress



Systemic MCA involves ≥2 organ systems, classified as clonal or non-clonal based on *KIT* D816V mutation status

- Systemic mast cell activation (MCA) is characterized by abnormal release of mast cell (MC) mediators^{1–3}
- Systemic mastocytosis (SM) is a clonal mast cell disease driven by *KIT* D816V in ~95% of cases^{4,5}
- The prevalence of *KIT* D816V–driven clonal mast cell disease in patients with MCA symptoms is not known



 SM in some cases is associated with hereditary alpha-tryptasemia (HaT), a genetic condition defined by an increased copy number for the *TPSAB1* gene, which encodes the α tryptase enzyme; this leads to elevated serum tryptase levels produced by MCs that can potentially worsen the severity of MCA conditions^{9–11}



FceR1, high-affinity IgE receptor; FcgR, high-affinity IgG receptor; MCA, mast cell activation; MRGPRX2, Mas-related G-protein coupled receptor member X2; *TPSAB1*, tryptase alpha/beta 1. 1. Jackson CW et al. *Int J Mol Sci.* 2021;22:11270; 2. González-de-Olano D et al. *Front Immunol.* 2017;8:792; 3. Akin C et al. *J Allergy Clin Immunol.* 2017;140:349–355; 4. Garcia-Montero AC et al. *Blood.* 2006;108:2366–2372; 5. Kristensen T et al. *J Mol Diagn.* 2011;13:180–188; 6. Theoharides TC et al. *N Engl J Med.* 2015;373(2):163-172; 7. Pardanani A. *Am J Hematol.* 2023;98(7):1097-1116; 8. Metcalfe DD et al. Overview of mast cells in human biology. In: Akin, C (eds) Mastocytosis. Springer, Cham. 2020; doi.org/10.1007/978-3-030-27820-5_1; 9. Lyons JJ et al. *J Allergy Clin Immunol.* 2021;14:622– 632; 10. Glover SC et al. *Ann Allergy Asthma Immunol.* 2022;128:460–461; 11. Bonadonna P et al. *Curr Opin Allergy Clin Immunol.* 2022;22:277–282.

KIT D816V and HaT screening are warranted to differentiate between overlapping symptoms of systemic MCA and SM

- Activating KIT mutations and elevated basal serum tryptase (BST) are minor diagnostic criteria of SM^{1-3,a}
- Per WHO guidelines, it is recommended to test for *KIT* D816V and serum tryptase at the first sign of disease^{2,4}

Hallmark symptoms of SM that should lead to increased suspicion include



- Maculopapular lesions with Darier's sign is a highly specific diagnostic feature⁵
- Wheal-and-flare reaction is elicited by stroking the lesion with a tongue spatula⁵



- **Anaphylaxis** with hypotension and syncope can occur⁶
- **50% of adult patients with SM** experience recurrent or unexplained anaphylaxis^{4,5}

Gastrointestinal

- Many patients report nausea, vomiting, and/or diarrhea^{6,7}
- Symptoms can be unpredictable and severe^{6,7}




- Bone
- **Osteoporosis occurs in 38%** of patients with ISM⁸; **osteosclerosis occurs in 2–19%**⁹ of patients and is associated with advanced disease⁸
- Unexplained osteoporosis, especially in young males, should raise suspicion for SM¹⁰



^aBST >20 ng/mL is a minor criterion; BST levels should be adjusted in the case of HaT.

HaT, hereditary alpha-tryptasemia; ISM, indolent systemic mastocytosis; MCA, mast cell activation; SM, systemic mastocytosis; WHO, World Health Organization. 1. © International Agency for Research on Cancer. Verstovek S et al. 2023. Systemic Mastocytosis. https://tumourclassification.iarc.who.int/chaptercontent/63/20. Beta online ahead of print. Accessed April 2, 2024; 2. Khoury JD et al. *Leukemia*. 2022;36:1703–1719; 3. Arber DA et al. *Blood*. 2022;140:1200–1228; 4. Pardanani A. *Am J Hematol*. 2023;98:1097–1116; 5. Hartmann K et al. *J Allergy Clin Immunol*. 2016;137:35–45; 6. Gilreath JA et al. *Clin Pharmacol*. 2019;11:77–92; 7. Jennings SV et al. *Immunol Allergy Clin North Am*. 2018;38:505–525; 8. Riffel P et al. *J Cancer Res Clin Oncol*. 2020;146:945–951; 9. Wang M et al. *Endocrinol Diabetes Metab Case Rep*. 2023;2023:22-0408; 10. Abramowitz JD et al. *Endocr Pract*. 2012;18:158–161.

PROSPECTOR: The first prospective, multicenter screening study evaluating the prevalence of peripheral blood *KIT* D816V mutation and HaT in patients with evidence of systemic MCA



PROSPECTOR¹ Key Inclusion Criteria:

Adults presenting with at least one of the three criteria below as evidence of systemic MCA



Involvement of \geq 2 organ systems^a (cardiovascular involvement necessary) and basal serum tryptase levels \geq 8 ng/mL



3

Severe anaphylaxis (Ring-Messmer grade ≥II) due to Hymenoptera sting

Severe anaphylaxis (Ring-Messmer grade \geq II) with cardiovascular involvement and event-related tryptase elevation fitting the formula 20% of baseline plus 2 ng/mL evaluated in \geq 1 event

www.eaaci.org

#EAACIcongress

Key exclusion criteria:

Patients previously diagnosed with any of the following WHO subclassifications: CM only, ISM, SSM, SM-AHN, ASM, MCL, MC sarcoma

^aInvolvement is characterized by skin (pruritus, urticaria, flushing and angioedema), cardiovascular (tachycardia, syncope, and hypotension), gastrointestinal (diarrhea, nausea, vomiting, and gastrointestinal cramping) or respiratory/naso-ocular (wheezing, conjunctival injection, and nasal stuffiness).


ASM, aggressive systemic mastocytosis; CM, cutaneous mastocytosis; Dx, diagnosis; GI, gastrointestinal; HaT, hereditary alpha-tryptasemia; ISM, indolent systemic mastocytosis; MC, mast cell; MCA, mast cell activation; MCL, mast cell leukemia; SM, systemic mastocytosis; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic mastocytosis; WHO, World Health Organization.

1. (PROSPECTOR) Screening Study Evaluating the Prevalence of the *KIT* D816V Mutation in Patients With Systemic Mast Cell Activation. NCT04811365. https://classic.clinicaltrials.gov/ct2/show/NCT04811365. Accessed April 18, 2024.



PROSPECTOR study design

Prospective, multicenter (US & EU), noninterventional KIT D816V screening study (NCT04811365)¹



Primary endpoint: Proportion of patients with *KIT* D816V mutation in PB¹

Key secondary endpoints¹:


• KIT D816V variant allele fraction in PB

• Prevalence of HaT, defined as the proportion of patients with an increased *TPSAB1* GCN encoding alpha-tryptase



ARUP, Associated Regional and University Pathologists; ddPCR, droplet digital polymerase chain reaction; EU, European Union; GCN, gene copy number; HaT, hereditary alpha-tryptasemia; LoD, limit of detection; *TPSAB1*, tryptase alpha/beta 1; UK, United Kingdom; US, United States. 1. (PROSPECTOR) Screening Study Evaluating the Prevalence of the *KIT* D816V Mutation in Patients With Systemic Mast Cell Activation. NCT04811365. https://classic.clinicaltrials.gov/ct2/show/NCT04811365. Accessed April 18, 2024; 2. Hartmann K et al. Presented at AAAAI 2024. Presentation 739.

KIT D816V mutation detected in 4% of patients with systemic MCA – 400× enriched compared with the general population






^a4.1%, n=369 with mutation absence/presence confirmed; limit of detection = 0.03%.


MC, mast cell; MCA, mast cell activation; PB, peripheral blood; SM, systemic mastocytosis; VAF, variant allele fraction.

1. Hartmann K et al. Presented at AAAAI 2024. Presentation739; 2. Brockow K. Immunology Allergy Clin North Am. 2014;34(2):283–295.


Detection of *KIT* **D816V was higher in patients who experienced severe anaphylaxis**



KIT D816V was detected proportionately across inclusion criteria




80% of patients positive for KIT D816V had BST <20 ng/mL






^aKIT D816V detection in patients with systemic MCA by BST level (n/N=365/381); patients missing a BST value (n=16).
^b1/15 (7%) patients positive for KIT D816V had HaT (BST = 11.9 ng/mL; TPSAB1 genotype 2β3α).
BST, basal serum tryptase; HaT, hereditary alpha-tryptasemia; MCA, mast cell activation; TPSAB1, tryptase alpha/beta 1.

Proportion of patients with HaT increased with BST levels; no patient with BST <8 ng/mL had HaT



 46/56 (82%) patients with BST >20.0 ng/mL had HaT without detectable KIT D816V



^aThe remaining 4 patients were negative for *KIT* D816V upon repeat local testing, and all 4 declined bone marrow testing. BST, basal serum tryptase; HaT, hereditary alpha-tryptasemia; MC, mast cell; MMAS, monoclonal mast cell activation syndrome; PB, peripheral blood; SM, systemic mastocytosis.

Conclusions

- In the PROSPECTOR trial, KIT D816V in PB was detected in 4% of patients with suspected MCA (15 of 381 screened) by ddPCR (LoD 0.03%); detection of clonal MC disease was enriched by >400× versus general SM prevalence of 1:10,000
 - Detection of KIT D816V was higher in patients who experienced severe anaphylaxis
- *KIT* D816V in PB was detected irrespective of BST levels
 - 80% of patients positive for KIT D816V had BST <20 ng/mL (threshold for minor diagnostic criteria); 20% of patients positive for KIT D816V had BST <11.4 ng/mL
- Interpretation of BST is closely connected to HaT status; proportion of patients with HaT increased with BST levels

- 75% of patients with BST >11.4 ng/mL had HaT
- Data are supportive of ECNM/AIM guidance for high-sensitivity screening for KIT D816V as a first step in diagnosis of SM¹
 - Consider repeat assessment in bone marrow if negative for KIT D816V mutation in PB despite clinical symptoms of SM or unexplained BST elevation > 11.4 ng/mL
- Clonal MC disease was detected in 78% of patients with BST > 11.4 ng/mL who were negative for both HaT and KIT D816V in PB, suggesting additional studies leveraging enrichment strategies and/or higher-sensitivity assays may be required

Patients with MCA with signs or symptoms of systemic involvement regardless of BST should initially be screened for *KIT* D816V with a high-sensitivity assay (LoD 0.03%) followed by a full evaluation for SM

AIM, American Initiative in Mast Cell Diseases; BST, basal serum tryptase; ddPCR; digital droplet polymerase chain reaction; ECNM, European Competence Network on Mastocytosis; HaT, hereditary alpha-tryptasemia; LoD, limit of detection; MC, mast cell; MCA, mast cell activation; PB, peripheral blood; SM, systemic mastocytosis. 1. Valent P et al. J Allergy Clin Immunol: In Practice. 2022;10:P1999–P2012.E6

www.eaaci.org

#EAACIconaress



Acknowledgements

- We thank the patients and their families for making this trial possible
- We thank the investigators and clinical trial teams who participated in the trial
- This study was funded by Blueprint Medicines Corporation, Cambridge, MA
- Medical writing and editorial support was provided by Srividya Venkitachalam, PhD, of Healthcare Consultancy Group, funded by Blueprint Medicines Corporation, Cambridge, MA, USA, according to current policies established by the International Committee of Medical Journal Editors and Good Publication Practice guidelines. The sponsor reviewed and provided feedback on the presentation. However, the authors had full editorial control and provided final approval of all content.

 www.eaaci.org

#EAACIconaress



EAACI Congress 2024 Valencia, Spain 31 May - 3 June

Revolutionising Patient Care Through the Power of Data Science



#EAACIcongress

www.eaaci.org

inni pos

VALENCIA